SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to a mixed reaction to earnings, with initial positive revenue overshadowed by a one-time tax charge and concerns about increased spending on AI infrastructure. The community is debating whether the dip is a buying opportunity or a sign of deeper issues with the company's investment strategy. Some investors believe the market is overreacting, while others are wary of Meta's increasing capital expenditures.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI is trending as the community rallies around its potential, emphasizing a conviction-based approach over hype. Talk centers on the token's strong community and resilience within the $SOL ecosystem, with many expressing a shared belief that 'we're all gonna make it.'

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid anticipation for an upcoming meeting between President Trump and China's President Xi, with trade deal hopes influencing market sentiment. Community members are actively discussing potential impacts on major tech companies following mixed earnings reports from key players like Microsoft and Meta, while some express concern about an over-reliance on a few top stocks. Investors are weighing the potential for further market gains against concerns about stretched valuations and the broader economic outlook.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending due to a significant post-earnings drop, sparking discussions about reduced guidance and declining customer traffic amid macroeconomic pressures. Community members are debating the company's valuation, food quality, portion sizes, and pricing, with some suggesting it's oversold and ripe for institutional investment while others point to waning popularity. The impact of tariffs and competition from other fast-casual restaurants like CAVA are also being considered.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it surpasses a $5 trillion market cap, fueled by exceptionally strong AI chip demand and CEO Jensen Huang's forecast of $500 billion in cumulative revenue through 2026; the community is closely watching Trump's upcoming meeting with President Xi for potential easing of China's Blackwell restrictions, while also weighing the potential impact of increased capex from major tech companies like Microsoft and Meta.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending due to a significant stock drop following disappointing earnings and a lowered outlook, prompting analysts to downgrade the stock. The community is discussing potential corporate fraud, a management shakeup, and whether this presents a buying opportunity or a value trap. Some are hopeful for a quick bounce, while others are wary of deeper declines and possible investigations.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending amid ongoing speculation about a potential merger with Warner Bros. Discovery ($WBD), with discussions focusing on offer prices and deal structures. Community chatter revolves around whether a deal will materialize and its potential impact, particularly as analysts debate the value and future of the combined entity, while others point to upcoming earnings and layoffs as key events to watch.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors analyze the implications of the company's recent earnings report, particularly regarding its AI spending and Azure cloud growth. Community discussions revolve around whether the earnings justify the current valuation and forward guidance. The broader context includes Microsoft's significant stake in OpenAI and its ongoing competition in the cloud computing arena against companies like Amazon and Google.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending as traders discuss a potential short squeeze and the stock's undervaluation following recent earnings and future growth prospects. Community members are focused on potential price targets and the possibility of a buyout, while also analyzing short interest and options activity. Speculation about analyst upgrades and the impact of potential government actions are contributing to the heightened interest.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet's stock is trending as traders discuss the company's recent earnings beat and growing excitement around its AI and cloud computing initiatives. Community members are highlighting Google's AI strategy and potential for further growth, particularly compared to other tech giants. Some are also discussing the impact of Google's capital expenditure plans and partnerships in the AI space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

Equity

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.


Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +32.00% and +21.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth

Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results...

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R...

Enanta Pharmaceuticals to Appeal Ruling Related to 953 Patent Infringement Lawsuit

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United...

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline...

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will...

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$10.63
Prev Close	$10.47
Open	$10.44
Dividend Yield	0.00%
50-Day Moving Average	$9.61
Beta	1.07
Avg. Volume	1.18M
PE Ratio	-2.46

52-Week High	$15.34
52-Week Low	$4.09
Market Capitalization	$306.71M
EPS (Annual)	-$5.49
Price to Book	2.87
Revenue Per Employee	$516,297.71
Enterprise Value/EBITDA	N/A

ENTA
Enanta Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ENTA News

ENTAEnanta Pharmaceuticals Inc